A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g

Genentech

Status and phase: Completed; Phase 3

Conditions: Psoriasis

Treatments: Drug: Raptiva (efalizumab)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00096603

ACD2601g

Details and patient eligibility

About

This is an open label, multicenter study designed to evaluate the safety and tolerability of efalizumab administered subcutaneously at weekly doses of 1.0 mg/kg in subjects with plaque psoriasis who previously participated in Study ACD2600g.

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed informed consent
• Previous participation in Study ACD2600g
• For women of childbearing potential, continued use of an acceptable method of contraception for the duration of the study

Exclusion criteria

• Any medical condition that, in the judgment of the investigator, would jeopardize the subject's safety following exposure to Efalizumab